Every Form 4 that Quest Diagnostics Inc. (DGX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DGX filings page.
QUEST DIAGNOSTICS INC (DGX) reported that CEO, President and director J. E. Davis sold 10,000 shares of common stock on September 1, 2026 at an average price of $242.72 per share in an open-market or private transaction. The transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the executive. Following this sale, Davis directly holds 122,423 shares of Quest Diagnostics common stock.
QUEST DIAGNOSTICS INC (DGX) disclosed that Michael E. Prevoznik, SVP & General Counsel, exercised 22,677 stock options at $112.17 per share into common stock and, on the same date, sold 16,010, 6,237 and 430 common shares at weighted average prices of $242.8755, $243.6275 and $244.5148, respectively. The exercised option position was reduced to 0, and he also made a 1,000‑share charitable gift of common stock. Following these transactions, 5,780 shares are held indirectly through the company’s 401(k)/Supplemental Deferred Compensation Plan. The exercise and sales were effected under a Rule 10b5‑1 sales plan adopted by the reporting person.
Quest Diagnostics Inc. executive Mark E. Delaney, SVP & Chief Commercial Officer, reported selling 1,600 shares of common stock on 2026-07-28 at an average price of $235.18 per share. The sale was executed under a Rule 10b5-1 sales plan, and he now directly holds 10,335 shares.
Quest Diagnostics executive Karthik Kuppusamy, SVP Clinical Solutions, reported a small acquisition of 37 shares of common stock at $206.807 per share under a broker-administered dividend reinvestment plan, eligible for deferred Form 5 reporting under Rule 16a-6 but reported early. His direct holdings total 13,557 shares, with additional indirect holdings of 358 shares in a trust and 1,691 shares in the company’s 401(k) Profit Sharing Plan.
Quest Diagnostics director Robert B. Carter reported a small acquisition of 11 shares of common stock on July 22, 2026 at $206.804 per share. The shares were acquired through a broker-administered dividend reinvestment plan under Rule 16a-6, bringing his direct holdings to 3,864 shares.
Quest Diagnostics Inc. director Vicky B Gregg reported acquiring 72 shares of common stock on 2026-07-22 through a dividend reinvestment plan administered by the reporting person's broker. The shares were credited at $206.8080 per share, bringing the reported direct holdings to 18,386 shares. The disclosure notes this dividend reinvestment transaction was eligible for deferred reporting on Form 5 under Rule 16a-6, but it was voluntarily reported earlier on Form 4.
Quest Diagnostics Inc. executive Patrick Plewman, SVP for Diagnostic Services, reported acquiring 46 shares of Common Stock on 2026-07-22 at $206.807 per share through a dividend reinvestment plan administered by his broker. After this small acquisition under Rule 16a-6, he directly holds 15,293 shares. The dividend reinvestment, which is eligible for deferred reporting on Form 5, has been voluntarily reported earlier on Form 4.
Quest Diagnostics director Timothy L. Main reported a small acquisition of 21 shares of common stock on 2026-07-22 at $206.81 per share. The shares were acquired through a broker-administered dividend reinvestment plan and are eligible for deferred reporting under Rule 16a-6, though he chose to report early. After this transaction, he directly holds 22,460 shares and indirectly holds 5,000 shares through a trust.
Quest Diagnostics Executive Vice President & CFO Sam Samad reported an acquisition of 102 shares of Quest Diagnostics common stock on July 22, 2026, at $206.807 per share in a grant/award transaction, bringing his directly held position to 33,478 shares.
Footnotes state the security represents an award of restricted share units and that the shares were acquired through a dividend reinvestment plan administered by his broker, which is eligible for deferred reporting on Form 5 under Rule 16a-6 but was voluntarily reported early.
Quest Diagnostics Inc. director Wright Lassiter III reported a small acquisition of common stock. On 2026-07-22, he acquired 6 shares at $206.813 per share through a dividend reinvestment plan administered by his broker, increasing his direct holdings to 10,323 shares. The transaction was eligible for deferred reporting on Form 5 under Rule 16a-6, but he chose to report it early on Form 4. The Rule 10b5-1 checkbox was not marked as a trading plan.
Quest Diagnostics Inc. executive Mark E. Delaney, SVP & Chief Commercial Officer, reported a small acquisition of 34.0000 shares of common stock on 2026-07-22 at 206.8070 per share through a broker-administered dividend reinvestment plan, which is eligible for deferred reporting on Form 5 under Rule 16a-6 but was reported early. Following this transaction, his direct holdings total 11935.0000 shares. A footnote notes that the security is described as common stock but represents an award of restricted share units.
Quest Diagnostics director Timothy C. Wentworth reported a routine compensation-related transaction involving deferred equity-based awards. He received 144 Phantom Stock Units, representing an elective deferral of his director cash compensation under the company’s Amended and Restated Deferred Compensation Plan for Directors. Each unit is tied to Quest Diagnostics common stock and is payable in cash when his service as a director ends. Following this grant, he holds 342 Phantom Stock Units in total. This filing reflects a non-cash grant/award acquisition rather than an open-market stock purchase or sale.
Quest Diagnostics senior vice president Karthik Kuppusamy exercised stock options and sold shares in a pre-planned trade. On 2026-06-04, he exercised options for 4,827 shares at $121.805 per share and 3,320 shares at $127.725, acquiring 8,147 shares of common stock through derivative exercises.
That same day, he completed an open-market sale of 8,147 common shares at $200.00 per share pursuant to a Rule 10b5-1 sales plan, converting option value into cash in a pre-arranged manner. Following these transactions, he directly held 13,510 common shares, with additional indirect holdings of 358 shares in a trust and 1,721 shares through the company’s 401(k) profit sharing plan.
Quest Diagnostics CEO and President J. E. Davis reported an open-market sale of 10,000 shares of Common Stock on June 1, 2026 at a price of $194.14 per share.
After this transaction, Davis directly holds 132,423 shares of Quest Diagnostics Common Stock. The sale was carried out under a pre-arranged Rule 10b5-1 sales plan adopted by the reporting person, indicating it was scheduled in advance rather than timed discretionarily.
Quest Diagnostics director Robert B. Carter received an equity award in the form of restricted stock units. On May 20, 2026, he acquired 1,142 shares of Common Stock at a stated price of $0.00 per share, reflecting a grant or award rather than an open-market purchase.
After this award, Carter directly holds 3,853 shares of Quest Diagnostics common stock in total. The filing does not show any sales or derivative exercises, indicating this was a routine compensation-related equity grant to a board member rather than a trading decision in the market.
Gregg Vicky B reported acquisition or exercise transactions in this Form 4 filing.
Quest Diagnostics director Vicky B. Gregg received a compensation-related stock award. She was granted 1,142 shares of Quest Diagnostics common stock in the form of restricted stock units at no cash cost. Following this award, she directly holds 18,314 shares of Quest Diagnostics common stock.
Diaz Luis reported acquisition or exercise transactions in this Form 4 filing.
Quest Diagnostics director Luis Diaz received an equity grant in the form of restricted stock units. On May 20, 2026, he was awarded 1,142 shares of Quest Diagnostics common stock at no purchase price, increasing his directly held stake to 5,196 shares. This represents routine stock-based compensation rather than an open-market trade.
Quest Diagnostics director Timothy L. Main received an award of 1,142 shares of Common Stock in the form of restricted stock units on May 20, 2026. The award was granted at $0.00 per share as part of his compensation and is classified as a grant or award acquisition. Following this transaction, his directly owned Common Stock holdings increased to 27,439 shares.
Quest Diagnostics Inc. director Timothy C. Wentworth received an award of 1,142 shares of Common Stock in the form of restricted stock units. The grant carried a price of $0.00 per share and increased his directly owned holdings to 1,358 shares after the transaction.
The total also reflects shares previously acquired through dividend reinvestment under the Amended and Restated Deferred Compensation Plan for Directors, as noted in the footnotes. This is a compensation-related equity award rather than an open-market stock purchase or sale.
Quest Diagnostics director Tracey Doi received an equity award tied to her board service. She acquired 1,142 shares of Common Stock as a grant with no cash price per share, described in the footnotes as an award of restricted stock units. After this award and related dividend reinvestments, she directly holds 7,748 shares.
Quest Diagnostics director Timothy M. Ring received an award of 1,142 restricted stock units of common stock, classified as a grant or other acquisition with no cash price per share. After this award, he directly holds 31,140 shares, including shares acquired through dividend reinvestment under the Amended and Restated Deferred Compensation Plan for Directors.
Quest Diagnostics Inc. director Wright Lassiter III received an equity grant of 1,142 shares of common stock on May 20, 2026, reported as a restricted stock unit award. Following this grant, he directly holds 10,317 shares, which include shares acquired through dividend reinvestment under the Deferred Compensation Plan for Directors.
Quest Diagnostics director Denise M. Morrison received an award of 1,142 shares of Common Stock on May 20, 2026 as a grant of restricted stock units. The award was made at no cash cost per share and increased her direct holdings to 11,929 shares.
The total includes shares acquired through dividend reinvestment since her last Form 4 under the Amended and Restated Deferred Compensation Plan for Directors.
Quest Diagnostics Inc. director Gary M. Pfeiffer received an award of 1,142 restricted stock units of common stock on May 20, 2026 at no cash cost, as part of his director compensation. After this grant, his direct holdings total 31,005 shares, which include shares acquired through dividend reinvestment under the Amended and Restated Deferred Compensation Plan for Directors.
Quest Diagnostics Executive Vice President & CFO Sam Samad reported an acquisition of 108 shares of common stock on April 20, 2026, at $194.698 per share. After this award, he holds 33,376 shares directly.
Footnotes state the transaction represents an award of restricted share units and reflects shares acquired through a dividend reinvestment plan administered by his broker, which he chose to report early rather than on a later Form 5.
Quest Diagnostics senior executive Patrick Plewman, SVP for Diagnostic Services, reported a small acquisition of company common stock. On April 20, 2026, he acquired 49 shares at $194.699 per share through a dividend reinvestment plan administered by his broker.
Following this transaction, Plewman directly holds 15,247 Quest Diagnostics shares. The filing notes that these dividend reinvestment plan shares are eligible for deferred reporting on Form 5 under Rule 16a-6, but he chose to report the acquisition early on this Form 4.
Quest Diagnostics director Vicky B. Gregg increased her direct holdings through a dividend reinvestment plan. On April 20, 2026, she acquired 68 shares of Quest Diagnostics common stock at $194.698 per share via a broker-administered dividend reinvestment program. Following this automatic acquisition, she directly owns 17,172 shares of common stock. The filing notes this dividend reinvestment transaction was eligible for deferred reporting on Form 5, but she chose to report it early on Form 4.
Quest Diagnostics director Robert B. Carter reported a small acquisition of company stock through a dividend reinvestment plan. On April 20, 2026, he acquired 7 shares of common stock at $194.699 per share, bringing his direct holdings to 2,711 shares.
The shares were acquired automatically under a broker-administered dividend reinvestment plan and are eligible for deferred reporting on Form 5 under Rule 16a-6. Carter chose to report this routine transaction early on Form 4.
Quest Diagnostics director Wright Lassiter III reported a small acquisition of company stock through a dividend reinvestment plan. On April 20, 2026, he acquired 6 shares of common stock at $194.699 per share, bringing his direct holdings to 9,063 shares after the transaction. The filing notes this dividend reinvestment transaction is eligible for deferred reporting under Rule 16a-6, but the director chose to report it early on Form 4.
Quest Diagnostics SVP Karthik Kuppusamy reported a small acquisition of 39 shares of common stock at $194.699 per share. The filing describes this as a small acquisition under Rule 16a-6 related to a dividend reinvestment plan. Following the transaction, he holds 13,490 shares directly, plus indirect holdings through a trust and the company’s 401(k) plan.
Quest Diagnostics senior executive Mark E. Delaney reported a small automatic share acquisition. On April 20, 2026, he acquired 37 shares of Quest Diagnostics common stock at $194.696 per share through a dividend reinvestment plan under Rule 16a-6. Following this transaction, he directly holds 11,901 common shares.
WENTWORTH TIMOTHY C reported acquisition or exercise transactions in this Form 4 filing.
Quest Diagnostics director Timothy C. Wentworth received an award of 198 phantom stock units linked to Quest Diagnostics common stock. These units were credited on account of his elective deferral of director cash compensation under the company’s Amended and Restated Deferred Compensation Plan for Directors and will be payable in cash when his service as a director ends.
WENTWORTH TIMOTHY C reported acquisition or exercise transactions in this Form 4 filing.
Quest Diagnostics director Timothy C. Wentworth received an equity award of 215 shares of Common Stock in the form of restricted stock units. The grant was reported at a price of $0.00 per share as compensation, not a market purchase. Following this award, his directly owned position reported in this filing is 215 shares.
Quest Diagnostics Executive Vice President & CFO Sam Samad reported two stock transactions involving the company’s common stock. On a performance stock award settlement, he acquired 13,947 shares at $204.86 per share, increasing his direct holdings to 40,988 shares.
On the same date, 7,720 shares were disposed of at $204.86 per share, delivered back to Quest Diagnostics solely to cover tax withholding obligations related to that performance share award, leaving him with 33,268 directly owned shares after the tax-related disposition.
Quest Diagnostics EVP Catherine T. Doherty reported multiple stock transactions involving company common shares. On March 4, 2026, she acquired 11,364 shares as a performance stock award at $204.86 per share, approved under Rule 16b-3(d).
On the same date, 5,806 shares were disposed of back to Quest Diagnostics solely to cover tax withholding obligations from that award at $204.86 per share. On March 5, 2026, she executed an open-market sale of 5,558 shares at an average price of $206.21 per share pursuant to a pre-established Rule 10b5-1 sales plan.
After these transactions, she directly owned 67,122 common shares. She also indirectly held 4,502 shares through company 401(k) and supplemental deferred compensation plans, with amounts based on plan account balances and the market price of Quest Diagnostics stock.
Quest Diagnostics senior executive Mark E. Delaney reported stock-based compensation activity involving company common stock. On March 4, 2026, he acquired 5,682 shares of Quest Diagnostics common stock at a value of $204.86 per share through the settlement of a performance stock award approved under Rule 16b-3(d).
On the same date, 2,326 shares of common stock were disposed of back to Quest Diagnostics solely to cover tax withholding obligations related to that award, as indicated in the footnotes. Following these transactions, Delaney directly owned 11,864 shares of Quest Diagnostics common stock.
Quest Diagnostics senior executive Michael E. Prevoznick reported several share movements in Quest Diagnostics Inc. common stock. On March 5, 2026, he completed an open-market sale of 3,878 shares at $206.21 per share under a pre-arranged Rule 10b5-1 sales plan, leaving him with 37,557 directly held shares after that trade.
On March 4, 2026, he received a grant or award of 7,232 shares at a reference price of $204.86 per share, issued in settlement of a performance stock award that had been approved under Rule 16b-3(d). Also on that date, 3,354 shares were disposed of back to Quest Diagnostics solely to cover tax withholding obligations from that award settlement.
Separately, the filing notes indirect ownership of 5,737 shares through the company’s 401(k) and Supplemental Deferred Compensation Plan, with these plan holdings accumulated periodically by the plan trustee.
Quest Diagnostics CEO and President J. E. Davis reported mixed equity transactions involving company stock. On a grant date of March 4, 2026, Davis acquired 51,652 shares of Quest Diagnostics common stock at a price of $204.86 per share, issued in settlement of a performance stock award approved under Rule 16b-3(d). In a related move, 26,414 shares of common stock were disposed of back to the issuer at $204.86 per share to cover tax withholding obligations from the settlement. After these transactions, Davis directly held 142,423 shares of Quest Diagnostics common stock.
Quest Diagnostics senior vice president for Diagnostic Services Patrick Plewman reported a mix of stock award activity, tax-related share disposition, and an open-market sale of common stock. On March 4, he acquired 5,682 shares as a grant or award at $204.86 per share, issued in settlement of a performance stock award approved under Rule 16b-3(d). On the same date, 2,827 shares were disposed of at $204.86 per share to Quest Diagnostics to cover tax withholding obligations from that award, leaving 18,053 shares directly owned afterward. On March 5, he sold 2,855 shares of common stock in an open-market transaction at $206.21 per share under a pre-arranged Rule 10b5-1 trading plan, resulting in direct ownership of 15,198 shares.
Quest Diagnostics executive Michael J. Deppe reported offsetting equity transactions involving company stock. He acquired 1,473 shares of Quest Diagnostics common stock on a grant/award basis tied to a performance stock award, valued at $204.86 per share, increasing his holdings at that moment to 35,946 shares.
On the same date, 750 shares were disposed of back to Quest Diagnostics at $204.86 per share solely to cover tax withholding obligations arising from the settlement of that performance stock award. After the tax-withholding disposition, Deppe directly owned 35,196 shares of Quest Diagnostics common stock.
Quest Diagnostics senior vice president Karthik Kuppusamy reported a mix of equity award activity and related share disposition. He acquired 6,200 shares of common stock on March 4, 2026 as stock issued in settlement of a performance stock award approved under Rule 16b-3(d). To cover tax withholding from this award, 2,628 shares of common stock at $204.86 per share were disposed of back to the issuer. After these transactions, he held 13,441 shares directly, plus additional indirect holdings of 358 shares by trust and 1,658 shares in a 401(k) plan, based on information from the plan administrator.
Quest Diagnostics executive Catherine T. Doherty reported sales and related share dispositions of company stock. On March 3, 2026, she executed an open-market sale of 632 shares of common stock at $207.73 per share, leaving 67,122 shares held directly.
On March 2, 2026, 648 shares were disposed of at $204.86 per share to cover tax obligations tied to the vesting of restricted share units, and the sale activity was carried out under a pre-arranged Rule 10b5-1 trading plan. She also holds 4,502 shares indirectly through a company 401(k)/profit sharing plan.
Quest Diagnostics Executive Vice President & CFO Sam Samad reported a Form 4 transaction involving common stock. On the reported date, he disposed of 869 shares at $204.86 per share in a tax-withholding transaction tied to the vesting of a prior restricted stock unit grant. This was a sale of shares to satisfy tax obligations rather than an open-market trade. After this transaction, he directly owned 27,041 shares of Quest Diagnostics common stock.
Quest Diagnostics senior vice president and general counsel Michael E. Prevoznik reported recent stock transactions. On March 3, he executed an open-market sale of 526 shares of common stock at $207.73 per share under a Rule 10b5-1 sales plan, leaving 37,557 shares held directly afterward. On March 2, 288 shares were disposed of at $204.86 per share to cover tax obligations from the vesting of restricted share units. He also has 5,737 shares held indirectly through company 401(k) and deferred compensation plans.
Quest Diagnostics CEO and President J. E. Davis reported two stock transactions in company common stock. He disposed of 2,968 shares at $204.86 per share to satisfy tax obligations from the vesting of a prior restricted share unit grant. He also completed an open-market sale of 10,000 shares at $212.52 per share under a pre-arranged Rule 10b5-1 sales plan. After these transactions, he directly holds 117,185 Quest Diagnostics shares.
Quest Diagnostics senior vice president Patrick Plewman reported two stock dispositions. He sold 410 shares of common stock in an open-market transaction at $207.73 per share under a Rule 10b5-1 sales plan he previously adopted.
He also disposed of 230 shares at $204.86 per share to cover tax obligations from the vesting of an earlier restricted share unit grant. After these transactions, he directly owns 15,198 shares of Quest Diagnostics common stock.
Quest Diagnostics senior vice president Karthik Kuppusamy disposed of 205 shares of common stock at $204.86 per share to cover tax obligations from vesting restricted share units. This tax-withholding transaction on March 2, 2026 was not an open-market sale. After the transaction, he held 9,869 shares directly, plus additional indirect holdings through a trust and the company’s 401(k) plan.
Quest Diagnostics senior vice president and chief commercial officer Mark E. Delaney reported a small, automatic share disposition related to taxes. On the transaction date, 188 shares of common stock were withheld at a price of $204.86 per share to satisfy tax obligations from vesting restricted share units. After this tax-withholding event, Delaney directly owned 8,508 Quest Diagnostics common shares.
Quest Diagnostics senior executive reports small tax-related share disposition. Michael J. Deppe, SVP, Corporate Controller and Chief Accounting Officer of Quest Diagnostics, had 88 shares of common stock withheld at $204.86 per share on a Form 4 event dated March 2, 2026 to satisfy tax obligations from previously vested restricted share units, rather than an open-market sale. After this transaction, he directly held 34,473 shares of Quest Diagnostics common stock. The filing also notes indirect ownership of 706 shares through the company’s 401(k) Profit Sharing Plan, with balances based on plan administrator data.
Quest Diagnostics senior vice president Patrick Plewman reported a mix of stock transactions and equity awards. On February 19, 2026, he completed an open‑market sale of 958 shares of common stock, leaving him with 15,838 shares held directly.
On February 18, 2026, he received a grant of 9,009 non-qualified stock options, which vest in three equal annual installments starting on the first anniversary of the grant date. He was also awarded 1,952 restricted stock units.
That same day, a total of 537 shares of common stock (244 shares at one price and 293 shares at another) were surrendered to the issuer solely to cover tax withholding obligations from vesting restricted stock units. The footnotes state the 958‑share sale was executed under a pre-arranged Rule 10b5‑1 trading plan adopted by Plewman.